<DOC>
	<DOCNO>NCT02356562</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy ombitasvir/ABT-450/r dasabuvir without Sofosbuvir RBV DAA treatment-experienced adult Genotype 1 Chronic Hepatitis C Virus infection .</brief_summary>
	<brief_title>A Study Evaluate Safety , Efficacy Pharmacokinetics Ombitasvir/ABT-450/Ritonavir Dasabuvir With Without Sofosbuvir RBV DAA Treatment-experienced Adults With Chronic Hepatitis C Virus Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>history previous direct act antiviral ( DAA ) therapy failure HCV genotype 1 infection Females must postmenopausal , nonchild bear potential practicing specific form birth control Positive screen hepatitis B surface antigen antihuman immunodeficiency virus antibody discontinuation prior DAA treatment reason virologic failure confirm presence hepatocellular carcinoma abnormal lab test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Interferon-Free</keyword>
	<keyword>Treatment Experienced</keyword>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Hepatitis C Virus</keyword>
</DOC>